戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ients (236 autologous, 128 reduced-intensity allogeneic, 113 myeloablative allogeneic) underwent stan
2 ety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM.
3                                      Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity o
4 e Washington State residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were freque
5                    We demonstrated that both allogeneic and syngeneic CAR T cells show initial expans
6 trong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.
7  immune-stimulatory molecules including semi-allogeneic antigens from maternal cells, substances from
8 r, they differ markedly in their response to allogeneic antigens, strongly promoting regulatory T-cel
9 ion (MR1/Rapa/100 cGy) and transplanted with allogeneic B10.D2 (H2) BMC.
10       We found improved engraftment of fully allogeneic BALB/c islets in Micro capsules transplanted
11 treat graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) put
12 es assessed the association of perioperative allogeneic blood transfusion, sepsis, and 5-year colon c
13 morrhage at cesarean section requires donor (allogeneic) blood transfusion.
14                                              Allogeneic BMC engraftment is enhanced with TGF-beta/Fc
15 Here, we demonstrate, using murine models of allogeneic BMT, that type 2 innate lymphoid cells (ILC2s
16 10/Fc, TGF-beta/Fc, or IL-2/Fc would enhance allogeneic bone marrow cell (BMC) engraftment and promot
17                      The test group received allogeneic bone marrow MSCs by intradiscal injection of
18 reconstitution and thymus regeneration after allogeneic bone marrow nucleated cell transplantation bu
19 s-host disease (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models.
20 sm and allograft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal con
21                                              Allogeneic bone marrow transplant from an HLA-matched si
22                                              Allogeneic bone marrow transplantation (allo-BMT) is a c
23 st disease (GVHD), a serious complication of allogeneic bone marrow transplantation (allo-BMT).
24 is a major cause of late mortality following allogeneic bone marrow transplantation (BMT) and is char
25                                              Allogeneic bone marrow transplantation has been attempte
26 ompare the safety and efficacy of 2 doses of allogeneic bone marrow-derived human mesenchymal stem ce
27 hough the efficiency of diabetes reversal of allogeneic but not syngeneic CC islets was lower than th
28 erentiated derivatives are not recognized as allogeneic by CD8(+) T cells, do not bind anti-HLA antib
29 ng repeated i.v. administration of activated allogeneic canine MSC.
30                          However, the use of allogeneic CAR T cells poses a concern in that it may in
31 ls, with a higher peak but rapid deletion of allogeneic CAR T cells.
32 represents a novel experience in humans with allogeneic cardiac stem cell in a rigorously imaging-bas
33 hether post-MI transendocardial injection of allogeneic CBSCs reduces pathological structural and fun
34          To understand the mechanism whereby allogeneic CD19 CAR T cells may mediate anti-lymphoma ac
35  and iDDC had a reduced ability to stimulate allogeneic CD4(+) T cells in the mixed-lymphocyte reacti
36 versial, potentially limiting the success of allogeneic cell combination therapy (ACCT).
37  progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immu
38                           On the other hand, allogeneic cells show several advantages over autologous
39 /or epigenomic manipulation of autologous or allogeneic cells.
40 lecular patterns have been well defined, how allogeneic cellular stimuli evoke innate responses remai
41 te prolonged and high levels of multilineage allogeneic chimerism and robust tolerance to the donor.
42 SCs:CD4(+)T-cell suppression was assessed in allogeneic coculture systems.
43                                              Allogeneic corneal transplantation was performed on infl
44 nts with cDGS underwent transplantation with allogeneic cultured thymus.
45 mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant model.
46 ects extensive genetic polymorphisms between allogeneic donors and recipients, most prominently withi
47 f intranodal administration of autologous or allogeneic DRibbles together with anti-OX40 antibody led
48 ling evidence that these cells can recognize allogeneic entities and that they mediate graft rejectio
49 ted tumor-specific T-cell dysfunction in the allogeneic environment.
50 d safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) i
51 ng autoimmune inflammatory bowel disease and allogeneic graft-versus-host disease.
52 stem that allows them to respond directly to allogeneic grafts is a topic of much debate.
53 esults provide new mechanistic insights into allogeneic GVT, validate the importance of targeting the
54                                              Allogeneic haematopoietic stem cell transplantation has
55  potential long-term neurological benefit of allogeneic haematopoietic stem cell transplantation in a
56 t cerebral adrenoleukodystrophy treated with allogeneic haematopoietic stem cell transplantation on a
57 ring to guide dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT).
58                                           In allogeneic HCT (allo-HCT), donor-derived T cells recogni
59             Limited data also support use of allogeneic HCT (alloHCT) in selected HIV-infected patien
60 of multiple dsDNA viruses was frequent after allogeneic HCT and had a dose-dependent association with
61 ipient pairs (8638 subjects) who received an allogeneic HCT and had archived pre-HCT peripheral blood
62 spectively tested weekly plasma samples from allogeneic HCT recipients at our center from 2007 to 201
63                            Reduced-intensity allogeneic HCT recipients showed evidence of delayed dec
64                     Conclusion Myeloablative allogeneic HCT recipients showed significant cognitive d
65                                    Among 404 allogeneic HCT recipients, including 125 cord blood, 125
66  present in 18.7% of autologous and 35.7% of allogeneic HCT recipients.
67 gic malignancies who underwent autologous or allogeneic HCT to inpatient palliative care integrated w
68 center cohorts, with clinical outcomes after allogeneic HCT within this prospective, multicenter stud
69 fied biomarkers with clinical outcomes after allogeneic HCT.
70 ng correlate with higher risks of GVHD after allogeneic HCT.
71  enhance GVL while minimizing GVHD following allogeneic HCT.
72 ogeneic splenocyte immunization in vivo, and allogeneic heart transplantation.
73                   The ability to distinguish allogeneic hematopoietic cell transplant (allo-HCT) reci
74 ronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred
75  clinical acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.
76                                              Allogeneic hematopoietic cell transplantation (allo-HCT)
77 ins a major life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT)
78                                              Allogeneic hematopoietic cell transplantation (allo-HCT)
79 se (GVHD), which is the main complication of allogeneic hematopoietic cell transplantation (allo-HCT)
80 f graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT)
81 in double-stranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are
82            We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from
83 t-versus-host disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from
84 Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is u
85 ase (GVHD) prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) rece
86                                              Allogeneic hematopoietic cell transplantation (HCT) repr
87 t-versus-host disease (GVHD) is common after allogeneic hematopoietic cell transplantation (HCT).
88  successful outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT).
89 t cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).
90 rment is well-recognized after myeloablative allogeneic hematopoietic cell transplantation (HCT).
91 treatment options for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo
92         A major barrier to successful use of allogeneic hematopoietic cell transplantation is acute g
93 yclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the o
94 major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation.
95  safety and immunogenicity results of MVA in allogeneic hematopoietic stem cell transplant (HCT) reci
96                               Autologous and allogeneic hematopoietic stem cell transplant (HSCT) pat
97 megalovirus (CMV) retinitis in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) pop
98  is a respiratory virus detected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) rec
99 with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT).
100 ry bowel disease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients
101 f PIV3-specific T cells and viral control in allogeneic hematopoietic stem cell transplant recipients
102 onic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a
103 mune responses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSC
104  is a frequent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo
105  immunity, have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo
106                                              Allogeneic hematopoietic stem cell transplantation (allo
107 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo
108 ental graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo
109 e of adult intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo
110    The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (allo
111 ngiogenesis has not been investigated during allogeneic hematopoietic stem cell transplantation (allo
112  Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT)
113 e a frequent and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT
114 mes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT
115 of morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT
116 t important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT
117 pstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT
118  solid-organ transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT
119 relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT
120                                              Allogeneic hematopoietic stem cell transplantation (HSCT
121                               The outcome of allogeneic hematopoietic stem cell transplantation (HSCT
122 sus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT
123                                              Allogeneic hematopoietic stem cell transplantation (HSCT
124                                              Allogeneic hematopoietic stem cell transplantation (HSCT
125                                              Allogeneic hematopoietic stem cell transplantation (HSCT
126 e antigen (anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT
127 sease (cGVHD) is a notorious complication of allogeneic hematopoietic stem cell transplantation and c
128 th advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and m
129    Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation conti
130 rvival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do no
131 s (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for m
132 ent with acute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from
133             The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in th
134                                              Allogeneic hematopoietic stem cell transplantation is ha
135 stress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recip
136                                          All allogeneic hematopoietic stem cell transplantation recip
137                   On the contrary, long-term allogeneic hematopoietic stem cell transplantation recip
138                                   Therefore, allogeneic hematopoietic stem cell transplantation shoul
139 l membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survi
140                               The success of allogeneic hematopoietic stem cell transplantation, a ke
141 ell-mediated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, sugg
142 se-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation.
143 s syndrome is a frequent condition following allogeneic hematopoietic stem cell transplantation.
144 n animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.
145 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.
146 ted with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more
147                     Twenty-one recipients of allogeneic hematopoietic stem cell transplants who under
148                                   The use of allogeneic hematopoietic stem cells (HSCs) to treat gene
149 ment of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT
150 t molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for M
151 yeloid leukemia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induc
152          Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, incl
153 d minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, rela
154  function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation.
155 utations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.
156 t of alloimmunity-induced autoimmunity after allogeneic hematopoietic transplantation.
157 ency are frequently related complications of allogeneic hematopoietic transplantation.
158  Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT)
159                                Most clinical allogeneic hemopoietic cell transplants (alloHCT) are no
160 t reactivity with myeloma patient sera after allogeneic HSCT and that may be significantly translocat
161 ge cerebral disease who were treated with an allogeneic HSCT and to identify disease- and treatment-r
162 pha-L-iduronidase, and patients treated with allogeneic HSCT at the onset have improved outcome, sugg
163 n's Hospital of Colorado (CHCO) who received allogeneic HSCT between January 2010 and December 2014.
164 ho were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had
165                    Among patients undergoing allogeneic HSCT for hematological malignancy, early admi
166            A total of 101 patients underwent allogeneic HSCT from January 2010 to December 2013; 32 (
167    These results establish a new preclinical allogeneic HSCT model for evaluation of GvHD prophylaxis
168 is significantly upregulated in the serum of allogeneic HSCT patients at aGVHD onset compared with no
169 recent cluster of CMV retinitis in pediatric allogeneic HSCT patients may suggest a rise in incidence
170                                    Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg-negati
171          The study cohort included 452 adult-allogeneic HSCT recipients, transplanted from 1997 to 20
172 ly in 1 045 peripheral blood samples from 98 allogeneic HSCT recipients.
173 tive to enzyme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for aden
174 atients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 wee
175 Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematop
176 ts had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation i
177  improve airflow decline-free survival after allogeneic HSCT.
178 ysiologically relevant, preclinical model of allogeneic HSCT.
179 2014 to December 2014, 28 patients underwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not
180  epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs
181 y, and efficacy of intracoronary delivery of allogeneic human cardiac stem cell in 55 patients with l
182 rica to determine the safety and efficacy of allogeneic human mesenchymal stem cells (MSCs) in reduci
183 ther 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocar
184 the reverse was true when the autologous and allogeneic IgG concentrations were augmented in allograf
185                                              Allogeneic immune cells, particularly T cells in donor g
186 text, we were able to visualize differential allogeneic immune synapse formation in polyclonal CD4(+)
187  In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sp
188       Ablation of HSCs impaired tolerance to allogeneic islet transplants in B6 recipients.
189 in MicroMix capsules improved engraftment of allogeneic islets in the IP site, but resulted deleterio
190 bated with T cells that were stimulated with allogeneic leukocytes or CD3/CD28 cross-linking.
191                                Using a fully allogeneic mismatched (BALB/c to C57BL/6) murine aortic
192 dentified upon T cell stimulation and during allogeneic MLR.
193 r-lateral left ventricular wall in C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n =
194 (REG)-dependent protection against IRI in an allogeneic mouse model.
195                                    In vitro, allogeneic mouse MSCs inhibited MRL.Fas(lpr) T cell prol
196                                              Allogeneic MSC therapy may be a valid alternative for th
197 nt here a randomized, controlled trial using allogeneic MSC, which are logistically more convenient t
198 AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of
199                     Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT0149203
200 jor histocompatibility complex (MHC)-matched allogeneic neural cell grafting in the brain, which is c
201 ZA) and decitabine (DAC) in combination with allogeneic NK cells generated from CD34(+) hematopoietic
202                            In the setting of allogeneic nonmyeloablative HSC transplants (HSCTs), sta
203 ognitive functioning after reduced-intensity allogeneic or autologous HCT remains unclear.
204 ls (RBC) isolated from knockout swine and to allogeneic or autologous human RBC.
205  had been immune rejections and responses of allogeneic or autologous stem cells.
206  were collected from draining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice
207 hestrate immune responses and destruction of allogeneic organ transplants, but how this process is re
208 3 patients with Ph(+) ALL with autologous or allogeneic (p190)BCR-ABL-specific CTLs.
209 -mediated skin injury caused by transferring allogeneic peripheral blood mononuclear cells more effec
210   Lack of immune cell penetration and T cell allogeneic priming was observed.
211 hronic disease complications and for whom an allogeneic procedure could present an unacceptable risk.
212 an antibody binding than human blood group O allogeneic RBC in 22% of tested sera.
213 ripotent stem cell (PSC)-derived products in allogeneic recipients.
214 ys for autologous recipients and 51 days for allogeneic recipients.
215 andard-issue (oldest available), compatible, allogeneic red cells (long-term storage group).
216 e either the freshest available, compatible, allogeneic red cells (short-term storage group) or stand
217  analysis using the Luminex platform, T cell allogeneic responses were measured by flow cytometry, an
218 e IDO-1 score (p = 0.007) and not undergoing allogeneic SCT (p = 0.007) was found to significantly pr
219                Of 349 patients who underwent allogeneic SCT during the study period, 92 patients (26%
220 asive monitoring of treatment response after allogeneic SCT for myelofibrosis.
221         In patients with an available donor, allogeneic SCT may also be considered.
222 of platelet counts among patients undergoing allogeneic SCT or chemotherapy and because platelet tran
223 assess prognostic factors of survival in all allogeneic SCT recipients admitted to the ICU between 20
224                           Early mortality of allogeneic SCT recipients admitted to the ICU is especia
225 earing CMV tet(low) and tet(high) CTLs after allogeneic SCT.
226 t increasing the CMV reactivation risk after allogeneic SCT.
227 enitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis.
228 by a phase 2 efficacy trial was conducted in allogeneic sibling donors.
229 d primary human B cells as well as in murine allogeneic skin transplant and alloantigen-induced T cel
230 esponses to allogeneic stimulation in vitro, allogeneic splenocyte immunization in vivo, and allogene
231                            Immunization with allogeneic splenocytes in vivo resulted in increased all
232  with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor l
233 graftment with a normal human donor to model allogeneic stem cell rescue.
234  IDO-1 score (p < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predic
235 ents, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enroll
236 study of 114 consecutive patients undergoing allogeneic stem cell transplant.
237  Chronic graft-vs-host-disease (cGVHD) after allogeneic stem cell transplantation (AHSCT) may resembl
238 ng 1 documented case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several
239 ate nonrelapse mortality and morbidity after allogeneic stem cell transplantation (allo-SCT).
240  of nonrelapse morbidity and mortality after allogeneic stem cell transplantation (allo-SCT).
241 1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit.
242                                              Allogeneic stem cell transplantation (SCT) has been prop
243 ge and after censoring patients who received allogeneic stem cell transplantation (SCT) in first remi
244                                 Admission of allogeneic stem cell transplantation (SCT) recipients to
245 V reactivation is a major complication after allogeneic stem cell transplantation (SCT).
246 consider additional studies and referral for allogeneic stem cell transplantation are also discussed.
247                                   Donors for allogeneic stem cell transplantation are preferentially
248                                              Allogeneic stem cell transplantation has the possibility
249 e of pathological immune responses following allogeneic stem cell transplantation resulting in acute
250 nitored 39 children shortly before and after allogeneic stem cell transplantation twice weekly by use
251 disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective
252 123) and DC-SIGN (rs11465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus
253 nogenic significance after HLA 10/10 matched allogeneic stem cell transplantation, we show that in th
254  common complication for patients undergoing allogeneic stem cell transplantation.
255 e of morbidity and mortality from GVHD after allogeneic stem cell transplantation.
256    The only curative option for CMML remains allogeneic stem cell transplantation.
257 elevated bleeding risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy
258 nditioning may reduce the rate of relapse in allogeneic stem cell transplants.
259  first remission and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible
260 MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from
261 ; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial ef
262 y may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-
263 ctory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation.
264  for adult and pediatric patients undergoing allogeneic stem-cell transplantation.
265 e patients in each treatment group underwent allogeneic stem-cell transplantation.
266 n of death in patients with acute GVHD after allogeneic stem-cell transplantation.
267 with acute GVHD who had received consecutive allogeneic stem-cell transplantation.
268 ced obesity and assessed immune responses to allogeneic stimulation in vitro, allogeneic splenocyte i
269 D70 serves as a unique negative regulator of allogeneic T cell response by contributing to donor T ce
270 ing role of BECs in a human ex vivo model of allogeneic T cell response, both in healthy subjects and
271      CD1(-) cDC were superior in stimulating allogeneic T cell responses and in cross-presenting vira
272 cause of its high permselectivity and strong allogeneic T cell responses.
273  among patients in their ability to suppress allogeneic T cells and in the use of either IL-17/argina
274                                Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT)
275                                              Allogeneic T cells from corneal transplant hosts promote
276                                              Allogeneic T cells from high-risk (HR) grafted mice indu
277 teins enabling subsequent ex vivo priming of allogeneic T cells with a specific cytokine signature.
278  direct antiproliferative effects of AzaC on allogeneic T cells.
279     Collectively, our data implicate Cdk5 in allogeneic T-cell responses after HCT and as an importan
280  histocompatibility complex class II reduces allogeneic T-cell responses in vitro and in vivo.
281                   Thus, adoptive transfer of allogeneic T9IL-33 cells offers an attractive approach f
282                         Murine DSAs bound to allogeneic targets expressed by islet cells and induced
283 ch a drug product (CTX-DP) was developed for allogeneic therapy.
284                                       During allogeneic tissue transplantation, the inhibition of lym
285 nomodulation may underlie the association of allogeneic transfusion with increased perioperative morb
286 rogate for NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60
287                           Mice that received allogeneic transplant showed an increase in nuclear 5-LO
288 highly educated patients more often received allogeneic transplantation (16.3% v 8.7%).
289 nts with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic
290 loablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplas
291 ngiogenesis occurred as early as day+2 after allogeneic transplantation mainly in GVHD typical target
292                                              Allogeneic transplantation of foreign organs or tissues
293 stitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depleted mice as r
294                                              Allogeneic transplantation was allowed.
295             We compared treatment intensity, allogeneic transplantation, and response rates by educat
296                In the mouse model of corneal allogeneic transplantation, galectin-8-induced lymphangi
297 D) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathoge
298 elopment of typical microvascular lesions in allogeneic transplants.
299 uced-intensity allogeneic, 113 myeloablative allogeneic) underwent standardized neuropsychologic test
300 ed four isogeneic (Lewis-to-Lewis) and seven allogeneic (Wistar-to-Lewis) ATx procedures.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top